Ali Behbahani is Director at Black Diamond Therapeutics, Inc. (BDTX). They have made 24 open-market trades across 15 companies since 2018, most recently 2026-09-18.
CIK 0001613867
20 open-market purchases totalling $243.9M since 2018, against 4 sales. Across 20 scored buys the stock is down 13.1% at ninety days, and 13.1 points behind the S&P over the same stretch.
20 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 45% | 40% | 40% |
| Avg Move | +1.3% | -7.2% | -13.1% |
| Alpha | +0.7% | -7.0% | -13.1% |
| Scored | 20 | 20 | 20 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SGP | BUY | 2026-02-09 | 2026-02-11 | $16.00 | $15.0M | +4.8% | -5.0% | -13.7% |
| NEUE | SELL | 2025-10-02 | 2025-10-06 | $6.75 | $25K | N/A | N/A | N/A |
| ADAP | SELL | 2025-08-15 | 2025-08-19 | $0.01 | $342K | -5.8% | +156.0% | N/A |
| MBX | BUY | 2024-09-16 | 2024-09-17 | $16.00 | $8.0M | +11.4% | +7.7% | -11.0% |
| SVRA | BUY | 2023-07-17 | 2023-07-19 | $3.00 | $1000K | +4.1% | +2.9% | +1.5% |
| BDTX | BUY | 2023-07-05 | 2023-07-06 | $5.00 | $5.0M | +5.4% | -26.7% | -44.7% |
| GNCA | SELL | 2022-05-24 | 2022-05-26 | $0.07 | $1.5M | N/A | N/A | N/A |
| TRVI | BUY | 2022-04-11 | 2022-04-13 | $1.90 | $13.6M | -4.1% | -24.3% | +22.3% |
| BHG | BUY | 2021-06-28 | 2021-06-30 | $18.00 | $35.0M | -6.6% | -36.5% | -51.3% |
| GLUE | BUY | 2021-06-28 | 2021-06-30 | $19.00 | $19.9M | -18.5% | +7.5% | +4.2% |
| MRKR | BUY | 2021-03-16 | 2021-03-18 | $1.75 | $20.0M | -2.7% | -14.0% | +46.8% |
| RGLS | BUY | 2020-12-04 | 2020-12-07 | $0.62 | $5.5M | +26.2% | +34.0% | +42.9% |
| MTCR | BUY | 2020-09-18 | 2020-09-22 | $13.00 | $10.0M | -6.0% | -15.0% | -26.3% |
| GNCA | BUY | 2020-07-24 | 2020-07-28 | $2.25 | $7.1M | -42.1% | -56.9% | -56.9% |
| AKUS | BUY | 2020-06-30 | 2020-07-01 | $17.00 | $10.0M | -3.0% | -12.3% | +3.8% |
| TRVI | SELL | 2020-04-03 | 2020-04-13 | $2.66 | $2K | -6.9% | -3.1% | +69.7% |
| BDTX | BUY | 2020-02-03 | 2020-02-05 | $19.00 | $15.2M | -4.7% | -21.6% | +2.5% |
| ADAP | BUY | 2020-01-24 | 2020-01-28 | $0.67 | $5.0M | +0.0% | -10.3% | -16.7% |
| MIRM | BUY | 2019-07-22 | 2019-07-24 | $15.00 | $6.8M | -5.9% | +0.4% | -47.4% |
| GNCA | BUY | 2019-06-24 | 2019-06-25 | $3.50 | $10.0M | +5.5% | -2.9% | -4.4% |
| TRVI | BUY | 2019-05-09 | 2019-05-13 | $10.00 | $25.0M | +12.5% | +3.2% | -36.4% |
| RGLS | BUY | 2019-05-07 | 2019-05-09 | $1.08 | $2.5M | -3.0% | -23.0% | -54.9% |
| GNCA | BUY | 2019-02-14 | 2019-02-19 | $0.47 | $9.4M | +43.6% | +35.7% | +25.2% |
| ADAP | BUY | 2018-09-07 | 2018-09-10 | $1.67 | $20.0M | +8.3% | +12.8% | -46.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| KRRO | 1,297,893 | $11.3M |
| TRVI | 948,948 | $11.3M |
| MRKR | 10,714,285 | $11.2M |
| AKUS | 513,758 | $6.8M |
| MTCR | 2,291,297 | $1.0M |
| ADAP | 14,671,794 | $805K |
| ACLX | 2,706 | $311K |
| GNCA | 4,445,093 | $227K |
| BDTX | 110,236 | $188K |
| UTRS | 58,279 | $86K |
| OYST | 3,573 | $40K |
| NVRO | 5,390 | $31K |
| CRSP | 256 | $13K |
| MIRM | 135 | $11K |
| CVRX | 316 | $414 |
| Total | $499.6M |
Shares reported on the most recent Form 4, priced at the 2026-09-21 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.